Income Statement
XILIO THERAPEUTICS, INC.
XLO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
43.77 | 6.34 | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
43.77 | 6.34 | - | - | - |
|
Operating Expenses
|
85.75 | 66.93 | 79.13 | 89.15 | 75.04 |
|
Research & Development
|
56.04 | 41.21 | 52.14 | 59.20 | 51.19 |
|
Selling, General & Administrative
|
29.71 | 24.78 | 27.00 | 29.95 | 23.86 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-41.98 | -60.58 | -79.13 | -89.15 | -75.04 |
|
Non-Operating Income
|
6.95 | 2.34 | 2.73 | 0.93 | - |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | 0.10 | 0.70 | 0.80 | 0.60 |
|
Other Non-Op Income / Expense
|
5.80 | 2.34 | 2.73 | 0.93 | -0.76 |
|
Income Before Tax
|
-35.04 | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-35.04 | -58.24 | -76.40 | -88.22 | -75.80 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-40.44 | -58.94 | -77.23 | -87.30 | -73.55 |
|
Earnings Per Share (Basic)
|
-4.19 | -1.09 | -2.78 | -3.22 | -13.52 |
|
Diluted EPS
|
-4.19 | -1.09 | -2.78 | -3.22 | -13.52 |
|
Weighted Average Shares
|
8.36 | 53.51 | 27.50 | 27.39 | 5.61 |
|
Diluted Weighted Avg Shares
|
- | - | - | - | - |
|
Comprehensive Income
|
-35.04 | -58.24 | -76.40 | -88.22 | -75.80 |